BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...said Les Funtleyder, healthcare portfolio manager at E Squared Capital Management.Targeted...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But...
BioCentury | Jul 10, 2020
Finance

After pouring into biotech in 2Q, will generalists stay or will they go?

...the backburner, he thinks it could become a more prominent as the election looms nearer. E Squared Capital Management’s...
BioCentury | Jul 10, 2020
Finance

With record fund flows, biotech a top sector for investors heading into 3Q20

...internally that you can’t ignore that backdrop as you think about your portfolio,” she added. E Squared Capital Management’s...
BioCentury | Apr 23, 2020
Finance

Market recalibrates Biogen’s valuation as aducanumab filing is delayed

...discussions with FDA. But FDA delays are never a good sign from Wall Street’s perspective, E Squared Capital Management’s...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...data, and not just dementia but things like Parkinson’s, migraine, and across the spectrum, ALS,” E Squared Capital Management’s...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

...to investors neither party really had an appetite to do significant damage to the industry,” E Squared Capital Management’s...
BioCentury | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

...activity, deals, drug approvals and clinical development progress,” Medical Strategy GmbH’s Mario Linimeier told BioCentury. E Squared Capital Management’s...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...fourth quarter of ‘18, I think investors are going to be a lot more picky,” E Squared Capital Management’s...
...too short a period of time, the IPO market could die of indigestion.” Les Funtleyder, E Squared Capital Management...
BioCentury | Feb 17, 2017
Financial News

Applied Therapeutics completes venture financing

...York, N.Y.) raised an undisclosed amount in a series A round with Alexandria Venture Investments, E Squared Capital Management...
Items per page:
1 - 10 of 11
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...said Les Funtleyder, healthcare portfolio manager at E Squared Capital Management.Targeted...
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But...
BioCentury | Jul 10, 2020
Finance

After pouring into biotech in 2Q, will generalists stay or will they go?

...the backburner, he thinks it could become a more prominent as the election looms nearer. E Squared Capital Management’s...
BioCentury | Jul 10, 2020
Finance

With record fund flows, biotech a top sector for investors heading into 3Q20

...internally that you can’t ignore that backdrop as you think about your portfolio,” she added. E Squared Capital Management’s...
BioCentury | Apr 23, 2020
Finance

Market recalibrates Biogen’s valuation as aducanumab filing is delayed

...discussions with FDA. But FDA delays are never a good sign from Wall Street’s perspective, E Squared Capital Management’s...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...data, and not just dementia but things like Parkinson’s, migraine, and across the spectrum, ALS,” E Squared Capital Management’s...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

...to investors neither party really had an appetite to do significant damage to the industry,” E Squared Capital Management’s...
BioCentury | Jan 1, 2020
Financial News

Fourth quarter rally pushes biotech to strong finish

...activity, deals, drug approvals and clinical development progress,” Medical Strategy GmbH’s Mario Linimeier told BioCentury. E Squared Capital Management’s...
BioCentury | Oct 4, 2019
Finance

Biotechs likely to flood IPO market ahead of 2020 election

...fourth quarter of ‘18, I think investors are going to be a lot more picky,” E Squared Capital Management’s...
...too short a period of time, the IPO market could die of indigestion.” Les Funtleyder, E Squared Capital Management...
BioCentury | Feb 17, 2017
Financial News

Applied Therapeutics completes venture financing

...York, N.Y.) raised an undisclosed amount in a series A round with Alexandria Venture Investments, E Squared Capital Management...
Items per page:
1 - 10 of 11